SubHero Banner

Dovato (dolutegravir and lamivudine) – New drug approval

April 8, 2019 - The FDA announced the approval of ViiV Healthcare’s Dovato (dolutegravir and lamivudine), as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults with no antiretroviral treatment history and with no known substitutions associated with resistance to the individual components of Dovato.

Download PDF